Evelo Biosciences to Present at Upcoming Investor Conferences in June

Rhea-AI Summary

Evelo Biosciences (Nasdaq:EVLO) announced its participation in three upcoming virtual investor conferences in June 2021. The events include: Jefferies Virtual Healthcare Conference on June 2 at 1:30 p.m. ET, JMP Securities Life Sciences Conference on June 16 at 1:00 p.m. ET, and Raymond James Human Health Innovation Conference on June 22 at 9:20 a.m. ET. Live audio webcasts will be available on their website, with replays accessible for 30 days post-event. Evelo is developing innovative orally delivered medicines targeting SINTAX, with four product candidates aimed at inflammatory diseases and cancer.

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will present at three upcoming virtual investor conferences in June:

Jefferies Virtual Healthcare Conference. Management will host a presentation at 1:30 p.m. ET on Wednesday, June 2, 2021.

JMP Securities Life Sciences Conference. Management will host a fireside chat at 1:00 p.m. ET on Wednesday, June 16, 2021.

Raymond James Human Health Innovation Conference. Management will host a presentation at 9:20 a.m. ET on Tuesday, June 22, 2021.

Live audio webcasts of the presentations will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. A replay of these webcasts will be available for approximately 30 days following each presentation.

About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered medicines that act on SINTAX™, the small intestinal axis, to have systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.

Contact
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com

FAQ

What upcoming investor conferences will Evelo Biosciences participate in June 2021?

Evelo Biosciences will participate in the Jefferies Virtual Healthcare Conference on June 2, the JMP Securities Life Sciences Conference on June 16, and the Raymond James Human Health Innovation Conference on June 22, 2021.

What time will Evelo's presentations occur during the conferences?

Evelo's presentations are scheduled for June 2 at 1:30 p.m. ET, June 16 at 1:00 p.m. ET, and June 22 at 9:20 a.m. ET.

Where can I watch Evelo Biosciences' conference presentations?

The presentations can be watched via live audio webcasts available on Evelo's Investors website.

What are the product candidates being developed by Evelo Biosciences?

Evelo is developing four product candidates: EDP1815, EDP1867, EDP2939 for inflammatory diseases, and EDP1908 for cancer.

What is the focus of Evelo Biosciences' drug development?

Evelo focuses on developing orally delivered medicines that target the small intestinal axis (SINTAX) to achieve systemic therapeutic effects.